


## Viral Epidemiology Snapshot: December 8-14, 2024


Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV						
<u>Virus</u>	#Tested	#Positive	% Positive			
Flu A	629	26	4.1%			
Flu B	629	6	1.0%			
RSV	470	121	25.7%			
CoV-2	548	25	4.6%			

Bacterial Respiratory Infections (Molecular Tests)						
<u>Organism</u>	#Tested	#Positive	% Positive			
Bordetella parapertussis	399	0	0.0%			
Bordetella pertussis	399	7	1.8%			
Chlamydia pneumoniae	387	0	0.0%			
Mycoplasma pneumoniae	394	25	6.3%			

Otner Respiratory viruses					
<u>Virus</u>	#Tested	#Positive	% Positive		
Adenovirus	387	28	7.2%		
Coronavirus 229E	387	0	0.0%		
Coronavirus HKU1	387	0	0.0%		
Coronavirus NL63	387	9	2.3%		
Coronavirus OC43	387	3	0.8%		
Metapneumovirus	387	6	1.6%		
Rhinovirus/Enterovirus	387	117	30.2%		
Parainfluenza 1	387	9	2.3%		
Parainfluenza 2	387	2	0.5%		
Parainfluenza 3	387	3	0.8%		
Parainfluenza 4	387	7	1.8%		





Flu A Subtyping				
2009 H1N1	5			
Seasonal H1	0			
Seasonal H3	3			
No Subtype	18			
Pending subtype	0			

This report contains results for all tests ordered throughout the CHMCA network. As of 9/19/23, the data set includes all Point of Care Testing performed at ACHPs and Urgent Care Centers, as well as the central hospital laboratories.

As of 10/1/23, SARS-CoV-2 will be tracked in total, rather than in "Diagnostic" and "Screening" categories

The top chart displays the 8-week trend for total number of positive tests for Flu A, Flu B, RSV, and SARS-CoV-2.

The bottom chart displays the 8-week trend for positivity rate (# positive/ total # tested) Flu A, Flu B, RSV, and SARS-CoV-2.

